Table 1.
Database covering 9 patient cohorts in MM listing number of patients, line of therapy, treatment arms and type of transcriptomic analysis performed.
| Discovery n = 1045 |
n | Type | Treatment | Analysis Platform |
|---|---|---|---|---|
| HOVON65/GMMG-HD4 | 327 | NDMM 1 | PAD/VAD 3 | Affymetrix Gene chip Plus 2.0 |
| UAMS-TT2 | 345 | NDMM | TD/VincristineDex 4 | Affymetrix Gene chip Plus 2.0 |
| MRC-IX non-IC | 109 | NDMM | CTDa/MP 5 | Affymetrix Gene chip Plus 2.0 |
| APEX | 264 | RRMM 2 | BOR/DEX 6 | Affymetrix Gene chip Plus A + B |
| Validation n = 609 |
||||
| HOVON87/NMSG18 | 178 | NDMM | MPT-T/MPR-R 7 | Affymetrix Gene chip Plus 2.0 |
| UAMS-TT3 | 238 | NDMM | VTD 8 | Affymetrix Gene chip Plus 2.0 |
| MRC-IX intensive | 138 | NDMM | CTD/CVAD 9 | Affymetrix Gene chip Plus 2.0 |
| UAMS-TT6 | 55 | RRMM | VTD | Affymetrix Gene chip Plus 2.0 |
| 2nd validation cohort n = 1000 |
||||
| CoMMpass | 718 | NDMM/RRMM | Multiple 1st, 2nd and 3rd regimens | RNAseq |
1. Newly diagnosed MM.; 2. Relapsed refractory MM; 3. Bortezomib/doxorubicin/dexamethsone and vincristine/doxorubicine/dexamethason.; 4. Thalidomide/dexamethason/vincristine; 5. Cyclophosphamide/thalidomide/dexamethasone/melphalan; 6. Bortezomib/dexamethasone; 7. Melphalan/prednisolone/thalidomide vs. melpahalan/prednisolone/lenalidomide; 8. Bortezomib/thalidomide/dexamethasone; 9. Cyclophosphamide/thalidomide/dexamethasone/melphalan/cyclophosfamide/vincristine/doxorubicin.